论文部分内容阅读
[目的]比较注射用紫杉醇脂质体与普通紫杉醇治疗非小细胞肺癌的疗效及毒副反应。[方法]非小细胞肺癌患者62例随机分为试验组和对照组。试验组(31例)给紫杉醇脂质体每次剂量135mg/m2;对照组(31例)给紫杉醇每次剂量135mg/m2。两组均联合顺铂治疗,每3周重复1次为1周期,共2周期。[结果]入组62例患者中,有60例患者毒副反应和疗效可供评价。试验组有效率27.0%,对照组有效率17.0%,两组疗效差异无统计学意义(P>0.05)。在血液学毒性方面,两组发生率差异无统计学意义(P>0.05)。在溶媒所产生的相关毒性方面,试验组发生率明显低于对照组,差异有统计学意义(P<0.05)。[结论]紫杉醇脂质体联合顺铂治疗非小细胞肺癌效果良好,两种紫杉醇的疗效相当,但其溶媒所产生的皮疹等过敏反应,紫杉醇脂质体明显低于紫杉醇,其余毒副反应相仿。
[Objective] To compare the efficacy and toxicity of paclitaxel-injected paclitaxel and paclitaxel in the treatment of non-small cell lung cancer. [Methods] 62 patients with non-small cell lung cancer were randomly divided into experimental group and control group. The experimental group (31 cases) gave paclitaxel liposomes every dose of 135mg / m2; control group (31 cases) paclitaxel each dose of 135mg / m2. Two groups were combined with cisplatin treatment, repeated once every 3 weeks for 1 cycle, a total of 2 cycles. [Results] Of the 62 patients enrolled in the study, 60 patients were eligible for evaluation of side effects and efficacy. The effective rate was 27.0% in the experimental group and 17.0% in the control group, with no significant difference between the two groups (P> 0.05). There was no significant difference in the hematological toxicity between the two groups (P> 0.05). The incidence of toxicity in the test group was significantly lower than that of the control group, the difference was statistically significant (P <0.05). [Conclusion] paclitaxel liposome combined with cisplatin is effective in the treatment of non-small cell lung cancer. The two paclitaxel have the same curative effect, but the allergic reactions such as rash caused by the vehicle and the paclitaxel liposome are obviously lower than the paclitaxel and the rest of the side effects are similar .